AMERICAN JOURNAL OF PSYCHIATRY
Fecha de publicación: 2 Mar 2018
DOI: https://doi.org/10.1176/appi.ajp.2017.17040410
Autores: Karolina Kauppi, Ph.D., Sara Brin Rosenthal, Ph.D., Min-Tzu Lo, Ph.D., Nilotpal Sanyal, Ph.D., Mian Jiang, B.S., Ruben Abagyan, Ph.D., Linda K. McEvoy, Ph.D., Ole A. Andreassen, M.D., Ph.D., Chi-Hua Chen, Ph.D.
Background: Antipsychotic drugs were incidentally discovered in the 1950s, but their mechanisms of action are still not understood. Better understanding of schizophrenia pathogenesis could shed light on actions of current drugs and reveal novel “druggable” pathways for unmet therapeutic needs. Recent genome-wide association studies offer unprecedented opportunities to characterize disease gene networks and uncover drug-disease relationships.
